Skip to main content

STRATEC Value Stock - Dividend - Research Selection

STRATEC Biomedical

ISIN: DE000STRA555, WKN: STRA55

Market price date: 17.05.2022
Market price: 102,20 EUR


STRATEC Biomedical Fundamental data and company key figures of the share

Annual reports in EUR
Key figures 15-04-2022
Cash flow
Net operating cash flow 63.473.000
Capital Expenditures -20.232.000
Free cash flow 43.241.000
Balance sheet
Total Equity 205.759.000
Liabilities & Shareholders equity 368.525.000
Income statement
Net income 39.958.000
Eps (diluted) 3,280
Diluted shares outstanding 12.126.100
Net sales/revenue 287.335.000

Fundamental ratios calculated on: 17-05-2022

Ratios
Key figures 17-05-2022
Cash flow
P/C 19,53
   
P/FC 28,66
Balance sheet
ROI10,84
ROE55,83
Income statement
P/E31,16
Div. Yield0,93%
P/B6,02
P/S4,31


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolSBS.DE
Market Capitalization1.503.077.504,00 USD
CountryGermany
IndicesCDAX,Prime All Share,SDAX
SectorsBiotechnology
Raw Data SourceIFRS in Millionen EUR
Stock Split2006-07-31,2.0000/1.0000; 2000-10-11,3.0000/1.0000
Internetwww.stratec-biomedical.de


Description of the company

Stratec Biomedical AG (STRATEC) is a Germany-based company engaged in the development and manufacture of fully automated systems based on its own patented technologies for its partners in the fields of clinical diagnostics and biotechnology. It is primarily active in the in vitro diagnostics industry and focuses on the segment in-vitro diagnostics, clinical diagnostics as well as molecular diagnostics. STRATEC's partners market Company's products to pharmaceutical laboratories, blood banks and research institutes throughout the world. As of December 31, 2011 the STRATEC Group operated through its four consolidated subsidiaries in Switzerland, the United Kingdom, Germany as well as the United States, comprising STRATEC Biomedical Switzerland AG, STRATEC Biomedical UK, Ltd, STRATEC Molecular GmbH and STRATEC Biomedical USA, Inc

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.stratec-biomedical.de


NEWS